Several compounds targeting EGFR have successfully entered clinical practice in cancer medicine including small molecules that bind the tyrosine kinase domain of EGFR such as gefitinib [14] (AstraZeneca, lung cancer) and erlotinib [15] (OSI/Genentech, lung and pancreatic cancer) and the monoclonal antibodies cetuximab [16](BMS/Imclone, colorectal, lung and head and neck cancer) and panitumumab [17] (Amgen, colorectal cancer) which bind its extracellular domain. This evidence concerns the gene EGFR and head and neck cancer.